[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Renal Cell Carcinoma in Kidney Transplant Recipients",
    "section": "",
    "text": "Characteristic\nOverall N = 1081\nPost Transplant N = 541\nPre Transplant N = 541\np-value2\n\n\n\n\nGender\n\n\n\n\n\n\n0.048\n\n\n    Female\n25 (23%)\n11 (20%)\n14 (26%)\n\n\n\n\n    Male\n58 (54%)\n35 (65%)\n23 (43%)\n\n\n\n\n    Unknown/Unspecified\n25 (23%)\n8 (15%)\n17 (31%)\n\n\n\n\nAge at transplant, y\n56 (47, 62)\n50 (40, 59)\n60 (52, 65)\n&lt;0.001\n\n\nAge at RCC, y\n55 (50, 64)\n55 (50, 64)\n56 (50, 63)\n0.9\n\n\nDonor status\n\n\n\n\n\n\n0.8\n\n\n    Deceased\n75 (69%)\n38 (70%)\n37 (69%)\n\n\n\n\n    Living\n33 (31%)\n16 (30%)\n17 (31%)\n\n\n\n\nPrincipal Diagnosis\n\n\n\n\n\n\n0.5\n\n\n    Hypertensive Nephrosclerosis\n32 (30%)\n13 (24%)\n19 (35%)\n\n\n\n\n    Diabetic Nephropathy\n20 (19%)\n12 (22%)\n8 (15%)\n\n\n\n\n    Glomerular Diseases\n16 (15%)\n10 (19%)\n6 (11%)\n\n\n\n\n    Unspecified/Other\n14 (13%)\n5 (9.3%)\n9 (17%)\n\n\n\n\n    Chronic Liver Disease/Hepatorenal Syndrome\n11 (10%)\n4 (7.4%)\n7 (13%)\n\n\n\n\n    Retransplantation/Graft Failure\n5 (4.6%)\n3 (5.6%)\n2 (3.7%)\n\n\n\n\n    Oncologic Indications\n4 (3.7%)\n2 (3.7%)\n2 (3.7%)\n\n\n\n\n    Amyloidosis\n2 (1.9%)\n2 (3.7%)\n0 (0%)\n\n\n\n\n    Other Nephrotoxicity\n2 (1.9%)\n1 (1.9%)\n1 (1.9%)\n\n\n\n\n    Polycystic Kidney Disease\n2 (1.9%)\n2 (3.7%)\n0 (0%)\n\n\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test"
  },
  {
    "objectID": "quarto/index.html#patient-characteristics-table",
    "href": "quarto/index.html#patient-characteristics-table",
    "title": "Renal Cell Carcinoma in Kidney Transplant Recipients",
    "section": "",
    "text": "Characteristic\nOverall N = 1081\nPost Transplant N = 541\nPre Transplant N = 541\np-value2\n\n\n\n\nGender\n\n\n\n\n\n\n0.048\n\n\n    Female\n25 (23%)\n11 (20%)\n14 (26%)\n\n\n\n\n    Male\n58 (54%)\n35 (65%)\n23 (43%)\n\n\n\n\n    Unknown/Unspecified\n25 (23%)\n8 (15%)\n17 (31%)\n\n\n\n\nAge at transplant, y\n56 (47, 62)\n50 (40, 59)\n60 (52, 65)\n&lt;0.001\n\n\nAge at RCC, y\n55 (50, 64)\n55 (50, 64)\n56 (50, 63)\n0.9\n\n\nDonor status\n\n\n\n\n\n\n0.8\n\n\n    Deceased\n75 (69%)\n38 (70%)\n37 (69%)\n\n\n\n\n    Living\n33 (31%)\n16 (30%)\n17 (31%)\n\n\n\n\nPrincipal Diagnosis\n\n\n\n\n\n\n0.5\n\n\n    Hypertensive Nephrosclerosis\n32 (30%)\n13 (24%)\n19 (35%)\n\n\n\n\n    Diabetic Nephropathy\n20 (19%)\n12 (22%)\n8 (15%)\n\n\n\n\n    Glomerular Diseases\n16 (15%)\n10 (19%)\n6 (11%)\n\n\n\n\n    Unspecified/Other\n14 (13%)\n5 (9.3%)\n9 (17%)\n\n\n\n\n    Chronic Liver Disease/Hepatorenal Syndrome\n11 (10%)\n4 (7.4%)\n7 (13%)\n\n\n\n\n    Retransplantation/Graft Failure\n5 (4.6%)\n3 (5.6%)\n2 (3.7%)\n\n\n\n\n    Oncologic Indications\n4 (3.7%)\n2 (3.7%)\n2 (3.7%)\n\n\n\n\n    Amyloidosis\n2 (1.9%)\n2 (3.7%)\n0 (0%)\n\n\n\n\n    Other Nephrotoxicity\n2 (1.9%)\n1 (1.9%)\n1 (1.9%)\n\n\n\n\n    Polycystic Kidney Disease\n2 (1.9%)\n2 (3.7%)\n0 (0%)\n\n\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test"
  },
  {
    "objectID": "quarto/index.html#surgery-characteristics-table",
    "href": "quarto/index.html#surgery-characteristics-table",
    "title": "Renal Cell Carcinoma in Kidney Transplant Recipients",
    "section": "Surgery Characteristics Table:",
    "text": "Surgery Characteristics Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 1081\nPost Transplant N = 541\nPre Transplant N = 541\np-value2\n\n\n\n\nTherapy\n\n\n\n\n\n\n0.12\n\n\n    Active Surveillance\n5 (4.6%)\n4 (7.4%)\n1 (1.9%)\n\n\n\n\n    Cryoablation\n12 (11%)\n7 (13%)\n5 (9.3%)\n\n\n\n\n    Immunotherapy\n2 (1.9%)\n2 (3.7%)\n0 (0%)\n\n\n\n\n    Nephrectomy\n86 (80%)\n41 (76%)\n45 (83%)\n\n\n\n\n    Unknown/Unspecified\n3 (2.8%)\n0 (0%)\n3 (5.6%)\n\n\n\n\nHistopathology\n\n\n\n\n\n\n0.2\n\n\n    Benign\n3 (2.8%)\n2 (3.7%)\n1 (1.9%)\n\n\n\n\n    Chromophobe\n4 (3.7%)\n3 (5.6%)\n1 (1.9%)\n\n\n\n\n    Clear Cell\n38 (35%)\n17 (31%)\n21 (39%)\n\n\n\n\n    Cystic\n5 (4.6%)\n0 (0%)\n5 (9.3%)\n\n\n\n\n    Oncocytic/Sarcomatoid\n5 (4.6%)\n4 (7.4%)\n1 (1.9%)\n\n\n\n\n    Papillary\n40 (37%)\n22 (41%)\n18 (33%)\n\n\n\n\n    Unclassified\n3 (2.8%)\n2 (3.7%)\n1 (1.9%)\n\n\n\n\n    Unknown/Unspecified\n10 (9.3%)\n4 (7.4%)\n6 (11%)\n\n\n\n\nGrading\n\n\n\n\n\n\n0.004\n\n\n    G1\n15 (14%)\n12 (22%)\n3 (5.6%)\n\n\n\n\n    G2\n28 (26%)\n18 (33%)\n10 (19%)\n\n\n\n\n    G3\n11 (10%)\n6 (11%)\n5 (9.3%)\n\n\n\n\n    G4\n2 (1.9%)\n1 (1.9%)\n1 (1.9%)\n\n\n\n\n    Unknown/Unspecified\n52 (48%)\n17 (31%)\n35 (65%)\n\n\n\n\nT-staging\n\n\n\n\n\n\n0.072\n\n\n    T1\n84 (78%)\n40 (74%)\n44 (81%)\n\n\n\n\n    T2\n6 (5.6%)\n5 (9.3%)\n1 (1.9%)\n\n\n\n\n    T3\n3 (2.8%)\n3 (5.6%)\n0 (0%)\n\n\n\n\n    T4\n1 (0.9%)\n1 (1.9%)\n0 (0%)\n\n\n\n\n    Unknown/Unspecified\n14 (13%)\n5 (9.3%)\n9 (17%)\n\n\n\n\n\n1 n (%)\n\n\n2 Fisher’s exact test"
  }
]